Denna sida har översatts automatiskt och översättningens korrekthet kan inte garanteras. Vänligen se engelsk version för en källtext.

Vagus nervstimulering för måttlig till svår reumatoid artrit (RESET-RA)

13 november 2026 uppdaterad av: SetPoint Medical Corporation

Vagus nervstimulering med hjälp av SetPoint-systemet för måttlig till svår reumatoid artrit: RESET-RA-studien

The RESET-RA study will assess the safety and efficacy of the SetPoint System (study device) for the treatment of adult patients with active, moderate to severe rheumatoid arthritis who have had an inadequate response or intolerance to biologic or targeted synthetic Disease-Modifying Anti-Rheumatic Drugs (DMARDs). The study device contains a miniaturized stimulator (implant) that is surgically placed under general anesthesia on the vagus nerve through a small incision on the left side of the neck (implant procedure). The study will enroll up to 250 subjects at up to 45 sites. All eligible subjects will undergo the implant procedure. Half of the subjects will receive active stimulation (treatment) and the other half will receive non-active stimulation (control). After completing primary endpoint assessments at Week 12, there will be a one-way crossover of control subjects to active stimulation and a 252-week open-label follow-up with all subjects (treatment and control) receiving active stimulation to evaluate long-term safety.

Studieöversikt

Detaljerad beskrivning

The RESET-RA study is an operationally seamless, 2-stage, randomized, double-blind, sham-controlled, multicenter pivotal study enrolling up to 250 subjects at up to 45 study centers across the U.S. The study will assess the safety and efficacy of the SetPoint System (study device) for the treatment of adult patients with active, moderate to severe rheumatoid arthritis (RA) who have had an inadequate response, loss of response or intolerance to biologic or targeted synthetic Disease-Modifying Anti-Rheumatic Drugs (DMARDs). The study device contains a miniaturized stimulator (implant) that is surgically implanted inside the left side of the neck on the vagus nerve (implant procedure). The implant delivers a small amount of electricity (stimulation) to the nerve. All eligible subjects will undergo the surgery under general anesthesia. Half of the subjects will receive active stimulation (the treatment group) and the other half will receive non-active stimulation (the control group). Stimulation will be delivered for 1 min once per day for 12 weeks. After completing primary endpoint assessments at Week 12, there will be a one-way crossover of control subjects to active stimulation and a 252-week open-label follow-up with all subjects (treatment and control) receiving active stimulation to evaluate long-term safety. Blinding will be maintained until the last enrolled and randomized subject in Stage 2 completes Week 12 assessments, and the study database is locked.

Studietyp

Interventionell

Inskrivning (Faktisk)

243

Fas

  • Fas 3

Kontakter och platser

Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.

Studieorter

    • Arizona
      • Mesa, Arizona, Förenta staterna, 85210
        • Arizona Arthritis ans Rheumatology Research, PPLC
      • Phoenix, Arizona, Förenta staterna, 85037
        • Arizona Arthritis Rheumatology & Research, PLLC
      • Tucson, Arizona, Förenta staterna, 85704
        • Arizona Arthritis & Rheumatology Research, PLLC
    • California
      • Covina, California, Förenta staterna, 91722
        • Medvin Clinical Research
      • Upland, California, Förenta staterna, 91786
        • Inland Rheumatology Clinical Trials
      • Whittier, California, Förenta staterna, 90602
        • Medvin Clinical Research
    • Colorado
      • Fort Collins, Colorado, Förenta staterna, 80528
        • The Arthritis & Rheumatology Clinic of Northern Colorado
    • Connecticut
      • Stamford, Connecticut, Förenta staterna, 06905
        • Stamford Therapeutics Consortium
    • Delaware
      • Lewes, Delaware, Förenta staterna, 19958
        • Delaware Arthritis
    • Florida
      • Aventura, Florida, Förenta staterna, 33180
        • Arthritis & Rheumatic Disease Specialties
      • Avon Park, Florida, Förenta staterna, 33825
        • HARAC Research Corporation
      • Boynton Beach, Florida, Förenta staterna, 33472
        • RecioMed Clinical Research Network, Inc.
      • Clearwater, Florida, Förenta staterna, 33765
        • Bay Area Rheumatology
      • Plantation, Florida, Förenta staterna, 33324
        • IRIS Research and Development
    • Georgia
      • Augusta, Georgia, Förenta staterna, 30912
        • Augusta University
      • Lawrenceville, Georgia, Förenta staterna, 30044
        • Parris and Associates Rheumatology
    • Illinois
      • Chicago, Illinois, Förenta staterna, 60611
        • Northwestern University
      • Willowbrook, Illinois, Förenta staterna, 60527
        • Willow Rheumatology and Wellness PLLC
    • Massachusetts
      • Boston, Massachusetts, Förenta staterna, 02114
        • Massachusetts General Hospital Division of Rheumatology, Allergy, and Immunology
    • Michigan
      • Lansing, Michigan, Förenta staterna, 48910
        • June DO, PC
    • Minnesota
      • Eagan, Minnesota, Förenta staterna, 55121
        • Saint Paul Rheumatology, P.A.
    • Missouri
      • Kansas City, Missouri, Förenta staterna, 64151
        • Kansas City Physician Partners
      • St Louis, Missouri, Förenta staterna, 63122
        • West County Rheumatology
    • Nebraska
      • Lincoln, Nebraska, Förenta staterna, 68516
        • Physician Research Collaboration, LLC
    • New Mexico
      • Albuquerque, New Mexico, Förenta staterna, 87102
        • Albuquerque Center for Rheumatology
    • New York
      • Babylon, New York, Förenta staterna, 11702
        • Long Island Regional Arthritis & Osteoporosis Care
    • North Carolina
      • Charleston, North Carolina, Förenta staterna, 28202
        • Arthritis & Osteoporosis Consultants Of The Carolinas
      • Charlotte, North Carolina, Förenta staterna, 28210
        • DJL Clinical Research
    • Oklahoma
      • Oklahoma City, Oklahoma, Förenta staterna, 73103
        • Health Research of Oklahoma, PLLC
      • Oklahoma City, Oklahoma, Förenta staterna, 73116
        • Rheumatology Associates of Oklahoma
    • Pennsylvania
      • Allentown, Pennsylvania, Förenta staterna, 18103
        • Lehigh Valley Health Network
      • Philadelphia, Pennsylvania, Förenta staterna, 19104
        • University of Pennsylvania Medical Center
    • Texas
      • Allen, Texas, Förenta staterna, 75013
        • Arthritis & Rheumatology Research Institute, PLLC
      • Austin, Texas, Förenta staterna, 78745
        • Tekton Research
      • Austin, Texas, Förenta staterna, 78717
        • Austin Regional Clinic
      • Austin, Texas, Förenta staterna, 78746
        • Central Texas Rheumatology Associates
      • Colleyville, Texas, Förenta staterna, 76034
        • Precision Comprehensive Clinical Research Solutions
      • Houston, Texas, Förenta staterna, 77043
        • Biopharma Informatic
      • Mesquite, Texas, Förenta staterna, 75150
        • Southwest Rheumatology Research LLC
      • San Antonio, Texas, Förenta staterna, 78229
        • Clinical Trials of Texas, Inc
    • Virginia
      • Fairfax, Virginia, Förenta staterna, 22033
        • Annapolis Rheumatology
    • Washington
      • Bothell, Washington, Förenta staterna, 98021
        • Sound Clinical Research, LLC
    • West Virginia
      • Morgantown, West Virginia, Förenta staterna, 26506
        • West Virginia University

Deltagandekriterier

Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.

Urvalskriterier

Åldrar som är berättigade till studier

22 år till 75 år (Vuxen, Äldre vuxen)

Tar emot friska volontärer

Nej

Kön som är behöriga för studier

Allt

Beskrivning

Inclusion Criteria:

  • 22-75 years of age at screening
  • Active moderate or severe RA, defined as at least 4/28 tender and 4/28 swollen joints
  • Demonstrated an inadequate response, loss of response, or intolerance to 1 or more approved for rheumatoid arthritis biologic or targeted synthetic Disease-Modifying Anti-Rheumatic Drugs (DMARDs), including Janus kinase inhibitors (JAKi)
  • Receiving treatment with at least 1 conventional synthetic DMARD for at least 12 weeks and on a continuous non-changing dose and route of administration for at least 4 weeks prior to Screening and able to continue the same stable dose through Week 12

Exclusion Criteria:

  • Untreated or poorly controlled psychiatric illness or history of substance abuse
  • Significant immunodeficiency due to underlying illness
  • History of stroke or transient ischemic attack, or diagnosis of cerebrovascular fibromuscular dysplasia
  • Clinically significant cardiovascular disease
  • Neurological syndromes, including multiple sclerosis, Alzheimer's disease, or Parkinson's disease
  • Uncontrolled fibromyalgia
  • History of left or right carotid surgery
  • History of unilateral or bilateral vagotomy, partial or complete splenectomy
  • Recurrent vasovagal syncope episodes
  • Current, regular use of tobacco products
  • Hypersensitivity/allergy to MRI contrast agents and/or unable to perform MRI

Studieplan

Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.

Hur är studien utformad?

Designdetaljer

  • Primärt syfte: Behandling
  • Tilldelning: Randomiserad
  • Interventionsmodell: Parallellt uppdrag
  • Maskning: Fyrdubbla

Vapen och interventioner

Deltagargrupp / Arm
Intervention / Behandling
Experimentell: Treatment

Active stimulation for 1 min once per day

The SetPoint System (study device) contains a miniaturized stimulator (implant) that is surgically implanted inside the left side of the neck on the vagus nerve (implant procedure). All eligible subjects will undergo the surgery under general anesthesia in outpatient settings.

Andra namn:
  • Kirurgisk placering av vagusnervstimulator inne i nacken

All subjects will continue to take at least one type of conventional synthetic DMARD at the same stable dose as for 4 weeks prior to consent

Andra namn:
  • Bakgrundsterapi med konventionell syntetisk DMARD

Active stimulation for 1 min once per day

Sham Comparator: Control

Non-active stimulation for 1 min once per day

The SetPoint System (study device) contains a miniaturized stimulator (implant) that is surgically implanted inside the left side of the neck on the vagus nerve (implant procedure). All eligible subjects will undergo the surgery under general anesthesia in outpatient settings.

Andra namn:
  • Kirurgisk placering av vagusnervstimulator inne i nacken

All subjects will continue to take at least one type of conventional synthetic DMARD at the same stable dose as for 4 weeks prior to consent

Andra namn:
  • Bakgrundsterapi med konventionell syntetisk DMARD

Non-active stimulation for 1 min once per day

Vad mäter studien?

Primära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
the American College of Rheumatology (ACR) 20 Response
Tidsram: Week 12

Response is defined as achieving at least 20% improvement from baseline to Week 12 in tender and swollen joint counts of 28 joints (scale 0=best to 28=worst) and 3 out of the following 5 measures: Health Assessment Questionnaire Disability Index (HAQ-DI) score (scale 0=no difficulty to 3=unable to do), subject global assessment (0=best to 10=worst), subject pain (0=no pain to 10=worst), evaluator's global assessment (0=best to 10=worst), or high sensitivity C-reactive protein (hsCRP) concentration (mg/L).

Week 12

Sekundära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
DAS28-CRP Good or Moderate Response as Defined by European League Against Rheumatism (EULAR)
Tidsram: Week 12

The Disease Activity Score in 28 joints calculated with C-reactive protein (DAS28-CRP) good or moderate response as defined by EULAR based on a composite score of 4 items: tender and swollen joint counts of 28 joints (scale 0=best to 28=worst), subject global assessment (0=best to 10=worst) and high-sensitivity C-reactive protein (hsCRP) concentration (mg/L). A total score ranges from 0 to 10 and is computed as follows:

DAS28-CRP = 0.56 * sqrt(TJC28) + 0.28 * sqrt(SJC28) + 0.36 * ln(CRP+1) + 0.014 * SGA + 0.96

A subject is considered having a moderate treatment response if:

  • DAS28-CRP score improvement from baseline to Week 12 is > 0.6 and ≤ 1.2, and the DAS28-CRP score at Week 12 is ≤ 5.1; or
  • DAS28-CRP score improvement from baseline to Week 12 is > 1.2, and the DAS28-CRP score at Week 12 is > 3.2.

A subject is considered having a good treatment response if:

• DAS28-CRP score improvement from baseline to Week 12 is > 1.2 and the DAS28-CRP score at Week 12 is ≤ 3.2

Week 12
DAS28-CRP Response (MCID -1.2) at Week 12
Tidsram: Week 12

The Disease Activity Score in 28 joints calculated with C-reactive protein (DAS28-CRP) response is based on the minimal clinically important difference (MCID) of -1.2 from baseline.

DAS28-CRP is based on a composite score of 4 items: tender and swollen joint counts of 28 joints (scale 0=best to 28=worst), subject global assessment (0=best to 10=worst) and high-sensitivity C-reactive protein (hsCRP) concentration (mg/L). A total score ranges from 0 to 10 and is computed as follows:

DAS28-CRP = 0.56 * sqrt(TJC28) + 0.28 * sqrt(SJC28) + 0.36 * ln(CRP+1) + 0.014 * SGA + 0.96

Week 12
Health Assessment Questionnaire Disability Index (HAQ-DI) Response (MCID -0.22)
Tidsram: Week 12

HAQ-DI response based on the MCID of -0.22 from baseline.

The HAQ-DI is a questionnaire validated for RA self-assessment by subjects that contains 20 questions in the following 8 functional areas:

  • Dressing and grooming
  • Arising
  • Eating
  • Walking
  • Hygiene
  • Reach
  • Grip
  • Common daily activities

Scoring within each functional area is from 0 (without any difficulty) to 3 (unable to do). The total score is obtained by summing 8 area scores and dividing by 8. The total HAQ-DI score ranges from 0 to 3 and corresponds to the current degree of disability:

  • 0 to < 1 Mild difficulties to moderate disability
  • 1 to < 2 Moderate disability
  • 2 to 3 Severe to very severe disability
Week 12
ACR20 Response at Week 12 From Day 0
Tidsram: Week 12

Response is defined as achieving at least 20% improvement from Day 0 to Week 12 in tender and swollen joint counts of 28 joints (scale 0=best to 28=worst) and 3 out of the following 5 measures: Health Assessment Questionnaire Disability Index (HAQ-DI) score (scale 0=no difficulty to 3=unable to do), subject global assessment (0=best to 10=worse), subject pain (0=no pain to 10=worst), evaluator's global assessment (0=best to 10=worst), or high sensitivity C-reactive protein (hsCRP) concentration (mg/mL).

Week 12

Andra resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Bone Erosion Progression, All Completers
Tidsram: Week 12

RAMRIS is a standardized system for RA MRI scoring of 4 different types of joint pathologies in the wrist and the hand. A total score for each pathology is generated by the summation of individual joint/bone scores as follows:

  • Synovitis: 8 joints each scored on a scale from 0 = normal to 3 = severe, resulting in a total score from 0 to 24.
  • Bone erosion: 25 bones each scored on a scale from 0 (0-10% eroded volume) to 10 (91-100% eroded volume), resulting in a total score from 0 to 250.
  • Osteitis: 25 bones scored on a scale from 0 (no osteitis) to 3 (68-100% of bone volume involved), resulting in a total score from 0 to 75.
  • CARLOS (cartilage loss): 25 joints each scored on a scale from 0 (no damage) to 4 (complete ankylosis or fusion), resulting in a total score from 0 to 100.

The proportion of bone erosion progressors is the % subjects with an increase of > 0.5 on the bone erosion score, comparing baseline to Week 12. An increase of > 0.5 represents disease progression.

Week 12
Bone Erosion Progression, All Completers With Erosive Phenotype
Tidsram: Week 12

RAMRIS is a standardized system for RA MRI scoring of 4 different types of joint pathologies in the wrist and the hand. A total score for each pathology is generated by the summation of individual joint/bone scores as follows:

  • Synovitis: 8 joints each scored on a scale from 0 = normal to 3 = severe, resulting in a total score from 0 to 24.
  • Bone erosion: 25 bones each scored on a scale from 0 (0-10% eroded volume) to 10 (91-100% eroded volume), resulting in a total score from 0 to 250.
  • Osteitis: 25 bones scored on a scale from 0 (no osteitis) to 3 (68-100% of bone volume involved), resulting in a total score from 0 to 75.
  • CARLOS (cartilage loss): 25 joints each scored on a scale from 0 (no damage) to 4 (complete ankylosis or fusion), resulting in a total score from 0 to 100.

The proportion of bone erosion progressors is the % subjects with an increase of > 0.5 on the bone erosion score, comparing baseline to Week 12. An increase of > 0.5 represents disease progression.

Week 12
Bone Erosion Progression, All Completers That Previously Only Failed 1 b/tsDMARD
Tidsram: Week 12

RAMRIS is a standardized system for RA MRI scoring of 4 different types of joint pathologies in the wrist and the hand. A total score for each pathology is generated by the summation of individual joint/bone scores as follows:

  • Synovitis: 8 joints each scored on a scale from 0 = normal to 3 = severe, resulting in a total score from 0 to 24.
  • Bone erosion: 25 bones each scored on a scale from 0 (0-10% eroded volume) to 10 (91-100% eroded volume), resulting in a total score from 0 to 250.
  • Osteitis: 25 bones scored on a scale from 0 (no osteitis) to 3 (68-100% of bone volume involved), resulting in a total score from 0 to 75.
  • CARLOS (cartilage loss): 25 joints each scored on a scale from 0 (no damage) to 4 (complete ankylosis or fusion), resulting in a total score from 0 to 100.

The proportion of bone erosion progressors is the % subjects with an increase of > 0.5 on the bone erosion score, comparing baseline to Week 12. An increase of > 0.5 represents disease progression.

Week 12
Change in Erosion Score, All Completers
Tidsram: Week 12

RAMRIS is a standardized system for RA MRI scoring of 4 different types of joint pathologies in the wrist and the hand (synovitis, bone erosion, osteitis, and cartilage loss). A total score for each pathology is generated by the summation of individual joint/bone scores:

• Bone erosion: 25 bones each scored on a scale from 0 (0-10% eroded volume) to 10 (91-100% eroded volume), resulting in a total score from 0 to 250.

Week 12
Change in Erosion Score, All Completers With Erosive Phenotype
Tidsram: Week 12

RAMRIS is a standardized system for RA MRI scoring of 4 different types of joint pathologies in the wrist and the hand (synovitis, bone erosion, osteitis, and cartilage loss). A total score for each pathology is generated by the summation of individual joint/bone scores:

• Bone erosion: 25 bones each scored on a scale from 0 (0-10% eroded volume) to 10 (91-100% eroded volume), resulting in a total score from 0 to 250.

Week 12
Change in Erosion Score, All Completers That Previously Only Failed 1 b/tsDMARD
Tidsram: Week 12

RAMRIS is a standardized system for RA MRI scoring of 4 different types of joint pathologies in the wrist and the hand (synovitis, bone erosion, osteitis, and cartilage loss). A total score for each pathology is generated by the summation of individual joint/bone scores:

• Bone erosion: 25 bones each scored on a scale from 0 (0-10% eroded volume) to 10 (91-100% eroded volume), resulting in a total score from 0 to 250.

Week 12
Change in Synovitis Score, All Completers
Tidsram: Week 12

RAMRIS is a standardized system for RA MRI scoring of 4 different types of joint pathologies in the wrist and the hand (synovitis, bone erosion, osteitis, and cartilage loss). A total score for each pathology is generated by the summation of individual joint/bone scores:

• Synovitis: 8 joints each scored on a scale from 0 = normal to 3 = severe, resulting in a total score from 0 to 24.

Week 12
Change in Synovitis Score, All Completers With Erosive Phenotype
Tidsram: Week 12

RAMRIS is a standardized system for RA MRI scoring of 4 different types of joint pathologies in the wrist and the hand (synovitis, bone erosion, osteitis, and cartilage loss). A total score for each pathology is generated by the summation of individual joint/bone scores:

• Synovitis: 8 joints each scored on a scale from 0 = normal to 3 = severe, resulting in a total score from 0 to 24.

Week 12
Change in Synovitis Score, All Completers That Previously Only Failed 1 b/tsDMARD
Tidsram: Week 12

RAMRIS is a standardized system for RA MRI scoring of 4 different types of joint pathologies in the wrist and the hand (synovitis, bone erosion, osteitis, and cartilage loss). A total score for each pathology is generated by the summation of individual joint/bone scores:

• Synovitis: 8 joints each scored on a scale from 0 = normal to 3 = severe, resulting in a total score from 0 to 24.

Week 12
Change in Osteitis Score, All Completers
Tidsram: Week 12

RAMRIS is a standardized system for RA MRI scoring of 4 different types of joint pathologies in the wrist and the hand (synovitis, bone erosion, osteitis, and cartilage loss). A total score for each pathology is generated by the summation of individual joint/bone scores:

• Osteitis: 25 bones scored on a scale from 0 (no osteitis) to 3 (68-100% of bone volume involved), resulting in a total score from 0 to 75.

Week 12
Change in Osteitis Score, All Completers With Erosive Phenotype
Tidsram: Week 12

RAMRIS is a standardized system for RA MRI scoring of 4 different types of joint pathologies in the wrist and the hand (synovitis, bone erosion, osteitis, and cartilage loss). A total score for each pathology is generated by the summation of individual joint/bone scores:

• Osteitis: 25 bones scored on a scale from 0 (no osteitis) to 3 (68-100% of bone volume involved), resulting in a total score from 0 to 75.

Week 12
Change in Osteitis Score, All Completers That Previously Only Failed 1 b/tsDMARD
Tidsram: Week 12

RAMRIS is a standardized system for RA MRI scoring of 4 different types of joint pathologies in the wrist and the hand (synovitis, bone erosion, osteitis, and cartilage loss). A total score for each pathology is generated by the summation of individual joint/bone scores:

• Osteitis: 25 bones scored on a scale from 0 (no osteitis) to 3 (68-100% of bone volume involved), resulting in a total score from 0 to 75.

Week 12
Clinical Disease Activity Index (CDAI) Low Disease Activity (LDA) or Remission
Tidsram: Week 12

The CDAI score is based on 4 items:

  • TJC28, tender joint count of 28 joints (scale 0=best to 28=worst)
  • SJC28, swollen joint count of 28 joints (scale 0=best to 28=worst)
  • SGA, subject global assessment (0=best to 10=worst)
  • EGA, evaluator's global assessment (0=best to 10=worst)

The CDAI score is calculated as follows and ranges from 0 to 76:

• CDAI = TJC28 + SJC28 + SGA + EGA

The CDAI score corresponds to the current RA activity:

  • 0 to ≤ 2.8 Remission
  • >2.8 to ≤ 10 Low disease activity (LDA)
  • >10 to ≤ 22 Moderate disease activity
  • > 22 High disease activity
Week 12
DAS28-CRP Low Disease Activity (LDA) or Remission
Tidsram: Week 12

The Disease Activity Score in 28 joints calculated with C-reactive protein (DAS28-CRP) score is a composite index providing a measure of disease activity, comprising:

  • TJC28, tender joint count of 28 joints (scale 0=best to 28=worst)
  • SJC28, swollen joint count of 28 joints (scale 0=best to 28=worst)
  • SGA, subject global assessment (0=best to 10=worst)
  • hsCRP (mg/L), high sensitivity C-reactive protein concentration (mg/L)

A total score ranges from 0 to 10 and is computed as follows:

DAS28-CRP = 0.56 * sqrt(TJC28) + 0.28 * sqrt(SJC28) + 0.36 * ln(CRP+1) + 0.014 * SGA + 0.96

The DAS28-CRP score corresponds to the current RA activity:

  • 0 to < 2.6 Remission
  • 2.6 to < 3.2 LDA
  • 3.2 to ≤ 5.1 Moderate activity
  • > 5.1 High activity
Week 12
the American College of Rheumatology (ACR) 20 Response, All Completers
Tidsram: Week 24

Response is defined as achieving at least 20% improvement from baseline to Week 12 in tender and swollen joint counts of 28 joints (scale 0=best to 28=worst) and 3 out of the following 5 measures: Health Assessment Questionnaire Disability Index (HAQ-DI) score (scale 0=no difficulty to 3=unable to do), subject global assessment (0=best to 10=worst), subject pain (0=no pain to 10=worst), evaluator's global assessment (0=best to 10=worst), or high sensitivity C-reactive protein (hsCRP) concentration (mg/L).

Week 24
the American College of Rheumatology (ACR) 20 Response, Non-augmented
Tidsram: Week 24

Response is defined as achieving at least 20% improvement from baseline to Week 12 in tender and swollen joint counts of 28 joints (scale 0=best to 28=worst) and 3 out of the following 5 measures: Health Assessment Questionnaire Disability Index (HAQ-DI) score (scale 0=no difficulty to 3=unable to do), subject global assessment (0=best to 10=worst), subject pain (0=no pain to 10=worst), evaluator's global assessment (0=best to 10=worst), or high sensitivity C-reactive protein (hsCRP) concentration (mg/L).

Week 24
Clinical Disease Activity Index (CDAI) Low Disease Activity (LDA) or Remission, All Completers
Tidsram: Week 24

The CDAI score is based on 4 items:

  • TJC28, tender joint count of 28 joints (scale 0=best to 28=worst)
  • SJC28, swollen joint count of 28 joints (scale 0=best to 28=worst)
  • SGA, subject global assessment (0=best to 10=worst)
  • EGA, evaluator's global assessment (0=best to 10=worst)

The CDAI score is calculated as follows and ranges from 0 to 76:

• CDAI = TJC28 + SJC28 + SGA + EGA

The CDAI score corresponds to the current RA activity:

  • 0 to ≤ 2.8 Remission
  • >2.8 to ≤ 10 Low disease activity (LDA)
  • >10 to ≤ 22 Moderate disease activity
  • > 22 High disease activity
Week 24
Clinical Disease Activity Index (CDAI) Low Disease Activity (LDA) or Remission, Non-augmented
Tidsram: Week 24

The CDAI score is based on 4 items:

  • TJC28, tender joint count of 28 joints (scale 0=best to 28=worst)
  • SJC28, swollen joint count of 28 joints (scale 0=best to 28=worst)
  • SGA, subject global assessment (0=best to 10=worst)
  • EGA, evaluator's global assessment (0=best to 10=worst)

The CDAI score is calculated as follows and ranges from 0 to 76:

• CDAI = TJC28 + SJC28 + SGA + EGA

The CDAI score corresponds to the current RA activity:

  • 0 to ≤ 2.8 Remission
  • >2.8 to ≤ 10 Low disease activity (LDA)
  • >10 to ≤ 22 Moderate disease activity
  • > 22 High disease activity
Week 24
DAS28-CRP Low Disease Activity (LDA) or Remission, All Completers
Tidsram: Week 24

The Disease Activity Score in 28 joints calculated with C-reactive protein (DAS28-CRP) score is a composite index providing a measure of disease activity, comprising:

  • TJC28, tender joint count of 28 joints (scale 0=best to 28=worst)
  • SJC28, swollen joint count of 28 joints (scale 0=best to 28=worst)
  • SGA, subject global assessment (0=best to 10=worst)
  • hsCRP (mg/L), high sensitivity C-reactive protein concentration (mg/L)

A total score ranges from 0 to 10 and is computed as follows:

DAS28-CRP = 0.56 * sqrt(TJC28) + 0.28 * sqrt(SJC28) + 0.36 * ln(CRP+1) + 0.014 * SGA + 0.96

The DAS28-CRP score corresponds to the current RA activity:

  • 0 to < 2.6 Remission
  • 2.6 to < 3.2 LDA
  • 3.2 to ≤ 5.1 Moderate activity
  • > 5.1 High activity
Week 24
DAS28-CRP Low Disease Activity (LDA) or Remission, Non-augmented
Tidsram: Week 24

The Disease Activity Score in 28 joints calculated with C-reactive protein (DAS28-CRP) score is a composite index providing a measure of disease activity, comprising:

  • TJC28, tender joint count of 28 joints (scale 0=best to 28=worst)
  • SJC28, swollen joint count of 28 joints (scale 0=best to 28=worst)
  • SGA, subject global assessment (0=best to 10=worst)
  • hsCRP (mg/L), high sensitivity C-reactive protein concentration (mg/L)

A total score ranges from 0 to 10 and is computed as follows:

DAS28-CRP = 0.56 * sqrt(TJC28) + 0.28 * sqrt(SJC28) + 0.36 * ln(CRP+1) + 0.014 * SGA + 0.96

The DAS28-CRP score corresponds to the current RA activity:

  • 0 to < 2.6 Remission
  • 2.6 to < 3.2 LDA
  • 3.2 to ≤ 5.1 Moderate activity
  • > 5.1 High activity
Week 24
Health Assessment Questionnaire Disability Index (HAQ-DI) MCID Response, All Completers
Tidsram: Week 24

HAQ-DI response based on the MCID of -0.22 from baseline.

The HAQ-DI is a questionnaire validated for RA self-assessment by subjects that contains 20 questions in the following 8 functional areas:

  • Dressing and grooming
  • Arising
  • Eating
  • Walking
  • Hygiene
  • Reach
  • Grip
  • Common daily activities

Scoring within each functional area is from 0 (without any difficulty) to 3 (unable to do). The total score is obtained by summing 8 area scores and dividing by 8. The total HAQ-DI score ranges from 0 to 3 and corresponds to the current degree of disability:

  • 0 to < 1 Mild difficulties to moderate disability
  • 1 to < 2 Moderate disability
  • 2 to 3 Severe to very severe disability
Week 24
Health Assessment Questionnaire Disability Index (HAQ-DI) Response (MCID -0.22), Non-augmented
Tidsram: Week 24

HAQ-DI response based on the MCID of -0.22 from baseline.

The HAQ-DI is a questionnaire validated for RA self-assessment by subjects that contains 20 questions in the following 8 functional areas:

  • Dressing and grooming
  • Arising
  • Eating
  • Walking
  • Hygiene
  • Reach
  • Grip
  • Common daily activities

Scoring within each functional area is from 0 (without any difficulty) to 3 (unable to do). The total score is obtained by summing 8 area scores and dividing by 8. The total HAQ-DI score ranges from 0 to 3 and corresponds to the current degree of disability:

  • 0 to < 1 Mild difficulties to moderate disability
  • 1 to < 2 Moderate disability
  • 2 to 3 Severe to very severe disability
Week 24
Study Participants That Are Somewhat to Very Satisfied With the SetPoint System for Treatment of Rheumatoid Arthritis
Tidsram: Week 24

Patient satisfaction was assessed at Week 24 using five-point Likert rating scale:

  • I am very dissatisfied
  • I am somewhat dissatisfied
  • I am neither satisfied nor dissatisfied
  • I am somewhat satisfied
  • I am very satisfied
Week 24
Study Participants That Are Neither Satisfied Nor Dissatisfied With the SetPoint System for Treatment of Rheumatoid Arthritis
Tidsram: Week 24

Patient satisfaction was assessed at Week 24 using five-point Likert rating scale:

  • I am very dissatisfied
  • I am somewhat dissatisfied
  • I am neither satisfied nor dissatisfied
  • I am somewhat satisfied
  • I am very satisfied
Week 24
Study Participants That Are Somewhat to Very Dissatisfied With the SetPoint System for Treatment of Rheumatoid Arthritis
Tidsram: Week 24

Patient satisfaction was assessed at Week 24 using five-point Likert rating scale:

  • I am very dissatisfied
  • I am somewhat dissatisfied
  • I am neither satisfied nor dissatisfied
  • I am somewhat satisfied
  • I am very satisfied
Week 24
Study Participants That Would Recommend the SetPoint System to a Family Member or Friend
Tidsram: Week 24

Patients were asked a question about whether they would recommend the SetPoint System to family and friends

Week 24
the American College of Rheumatology (ACR) 20 Response, All Completers
Tidsram: Week 36

Response is defined as achieving at least 20% improvement from baseline to Week 12 in tender and swollen joint counts of 28 joints (scale 0=best to 28=worst) and 3 out of the following 5 measures: Health Assessment Questionnaire Disability Index (HAQ-DI) score (scale 0=no difficulty to 3=unable to do), subject global assessment (0=best to 10=worst), subject pain (0=no pain to 10=worst), evaluator's global assessment (0=best to 10=worst), or high sensitivity C-reactive protein (hsCRP) concentration (mg/L).

Week 36
the American College of Rheumatology (ACR) 20 Response, Non-augmented
Tidsram: Week 36

Response is defined as achieving at least 20% improvement from baseline to Week 12 in tender and swollen joint counts of 28 joints (scale 0=best to 28=worst) and 3 out of the following 5 measures: Health Assessment Questionnaire Disability Index (HAQ-DI) score (scale 0=no difficulty to 3=unable to do), subject global assessment (0=best to 10=worst), subject pain (0=no pain to 10=worst), evaluator's global assessment (0=best to 10=worst), or high sensitivity C-reactive protein (hsCRP) concentration (mg/L).

Week 36
Clinical Disease Activity Index (CDAI) Low Disease Activity (LDA) or Remission, All Completers
Tidsram: Week 36

The CDAI score is based on 4 items:

  • TJC28, tender joint count of 28 joints (scale 0=best to 28=worst)
  • SJC28, swollen joint count of 28 joints (scale 0=best to 28=worst)
  • SGA, subject global assessment (0=best to 10=worst)
  • EGA, evaluator's global assessment (0=best to 10=worst)

The CDAI score is calculated as follows and ranges from 0 to 76:

• CDAI = TJC28 + SJC28 + SGA + EGA

The CDAI score corresponds to the current RA activity:

  • 0 to ≤ 2.8 Remission
  • >2.8 to ≤ 10 Low disease activity (LDA)
  • >10 to ≤ 22 Moderate disease activity
  • > 22 High disease activity
Week 36
Clinical Disease Activity Index (CDAI) Low Disease Activity (LDA) or Remission, Non-augmented
Tidsram: Week 36

The CDAI score is based on 4 items:

  • TJC28, tender joint count of 28 joints (scale 0=best to 28=worst)
  • SJC28, swollen joint count of 28 joints (scale 0=best to 28=worst)
  • SGA, subject global assessment (0=best to 10=worst)
  • EGA, evaluator's global assessment (0=best to 10=worst)

The CDAI score is calculated as follows and ranges from 0 to 76:

• CDAI = TJC28 + SJC28 + SGA + EGA

The CDAI score corresponds to the current RA activity:

  • 0 to ≤ 2.8 Remission
  • >2.8 to ≤ 10 Low disease activity (LDA)
  • >10 to ≤ 22 Moderate disease activity
  • > 22 High disease activity
Week 36
DAS28-CRP Low Disease Activity (LDA) or Remission, All Completers
Tidsram: Week 36

The Disease Activity Score in 28 joints calculated with C-reactive protein (DAS28-CRP) score is a composite index providing a measure of disease activity, comprising:

  • TJC28, tender joint count of 28 joints (scale 0=best to 28=worst)
  • SJC28, swollen joint count of 28 joints (scale 0=best to 28=worst)
  • SGA, subject global assessment (0=best to 10=worst)
  • hsCRP (mg/L), high sensitivity C-reactive protein concentration (mg/L)

A total score ranges from 0 to 10 and is computed as follows:

DAS28-CRP = 0.56 * sqrt(TJC28) + 0.28 * sqrt(SJC28) + 0.36 * ln(CRP+1) + 0.014 * SGA + 0.96

The DAS28-CRP score corresponds to the current RA activity:

  • 0 to < 2.6 Remission
  • 2.6 to < 3.2 LDA
  • 3.2 to ≤ 5.1 Moderate activity
  • > 5.1 High activity
Week 36
DAS28-CRP Low Disease Activity (LDA) or Remission, Non-augmented
Tidsram: Week 36

The Disease Activity Score in 28 joints calculated with C-reactive protein (DAS28-CRP) score is a composite index providing a measure of disease activity, comprising:

  • TJC28, tender joint count of 28 joints (scale 0=best to 28=worst)
  • SJC28, swollen joint count of 28 joints (scale 0=best to 28=worst)
  • SGA, subject global assessment (0=best to 10=worst)
  • hsCRP (mg/L), high sensitivity C-reactive protein concentration (mg/L)

A total score ranges from 0 to 10 and is computed as follows:

DAS28-CRP = 0.56 * sqrt(TJC28) + 0.28 * sqrt(SJC28) + 0.36 * ln(CRP+1) + 0.014 * SGA + 0.96

The DAS28-CRP score corresponds to the current RA activity:

  • 0 to < 2.6 Remission
  • 2.6 to < 3.2 LDA
  • 3.2 to ≤ 5.1 Moderate activity
  • > 5.1 High activity
Week 36
Health Assessment Questionnaire Disability Index (HAQ-DI) MCID Response, All Completers
Tidsram: Week 36

HAQ-DI response based on the MCID of -0.22 from baseline.

The HAQ-DI is a questionnaire validated for RA self-assessment by subjects that contains 20 questions in the following 8 functional areas:

  • Dressing and grooming
  • Arising
  • Eating
  • Walking
  • Hygiene
  • Reach
  • Grip
  • Common daily activities

Scoring within each functional area is from 0 (without any difficulty) to 3 (unable to do). The total score is obtained by summing 8 area scores and dividing by 8. The total HAQ-DI score ranges from 0 to 3 and corresponds to the current degree of disability:

  • 0 to < 1 Mild difficulties to moderate disability
  • 1 to < 2 Moderate disability
  • 2 to 3 Severe to very severe disability
Week 36
Health Assessment Questionnaire Disability Index (HAQ-DI) Response (MCID -0.22), Non-augmented
Tidsram: Week 36

HAQ-DI response based on the MCID of -0.22 from baseline.

The HAQ-DI is a questionnaire validated for RA self-assessment by subjects that contains 20 questions in the following 8 functional areas:

  • Dressing and grooming
  • Arising
  • Eating
  • Walking
  • Hygiene
  • Reach
  • Grip
  • Common daily activities

Scoring within each functional area is from 0 (without any difficulty) to 3 (unable to do). The total score is obtained by summing 8 area scores and dividing by 8. The total HAQ-DI score ranges from 0 to 3 and corresponds to the current degree of disability:

  • 0 to < 1 Mild difficulties to moderate disability
  • 1 to < 2 Moderate disability
  • 2 to 3 Severe to very severe disability
Week 36
the American College of Rheumatology (ACR) 20 Response, All Completers
Tidsram: Week 48

Response is defined as achieving at least 20% improvement from baseline to Week 12 in tender and swollen joint counts of 28 joints (scale 0=best to 28=worst) and 3 out of the following 5 measures: Health Assessment Questionnaire Disability Index (HAQ-DI) score (scale 0=no difficulty to 3=unable to do), subject global assessment (0=best to 10=worst), subject pain (0=no pain to 10=worst), evaluator's global assessment (0=best to 10=worst), or high sensitivity C-reactive protein (hsCRP) concentration (mg/L).

Week 48
the American College of Rheumatology (ACR) 20 Response, Non-augmented
Tidsram: Week 48

Response is defined as achieving at least 20% improvement from baseline to Week 12 in tender and swollen joint counts of 28 joints (scale 0=best to 28=worst) and 3 out of the following 5 measures: Health Assessment Questionnaire Disability Index (HAQ-DI) score (scale 0=no difficulty to 3=unable to do), subject global assessment (0=best to 10=worst), subject pain (0=no pain to 10=worst), evaluator's global assessment (0=best to 10=worst), or high sensitivity C-reactive protein (hsCRP) concentration (mg/L).

Week 48
Clinical Disease Activity Index (CDAI) Low Disease Activity (LDA) or Remission, All Completers
Tidsram: Week 48

The CDAI score is based on 4 items:

  • TJC28, tender joint count of 28 joints (scale 0=best to 28=worst)
  • SJC28, swollen joint count of 28 joints (scale 0=best to 28=worst)
  • SGA, subject global assessment (0=best to 10=worst)
  • EGA, evaluator's global assessment (0=best to 10=worst)

The CDAI score is calculated as follows and ranges from 0 to 76:

• CDAI = TJC28 + SJC28 + SGA + EGA

The CDAI score corresponds to the current RA activity:

  • 0 to ≤ 2.8 Remission
  • >2.8 to ≤ 10 Low disease activity (LDA)
  • >10 to ≤ 22 Moderate disease activity
  • > 22 High disease activity
Week 48
Clinical Disease Activity Index (CDAI) Low Disease Activity (LDA) or Remission, Non-augmented
Tidsram: Week 48

The CDAI score is based on 4 items:

  • TJC28, tender joint count of 28 joints (scale 0=best to 28=worst)
  • SJC28, swollen joint count of 28 joints (scale 0=best to 28=worst)
  • SGA, subject global assessment (0=best to 10=worst)
  • EGA, evaluator's global assessment (0=best to 10=worst)

The CDAI score is calculated as follows and ranges from 0 to 76:

• CDAI = TJC28 + SJC28 + SGA + EGA

The CDAI score corresponds to the current RA activity:

  • 0 to ≤ 2.8 Remission
  • >2.8 to ≤ 10 Low disease activity (LDA)
  • >10 to ≤ 22 Moderate disease activity
  • > 22 High disease activity
Week 48
DAS28-CRP Low Disease Activity (LDA) or Remission, All Completers
Tidsram: Week 48

The Disease Activity Score in 28 joints calculated with C-reactive protein (DAS28-CRP) score is a composite index providing a measure of disease activity, comprising:

  • TJC28, tender joint count of 28 joints (scale 0=best to 28=worst)
  • SJC28, swollen joint count of 28 joints (scale 0=best to 28=worst)
  • SGA, subject global assessment (0=best to 10=worst)
  • hsCRP (mg/L), high sensitivity C-reactive protein concentration (mg/L)

A total score ranges from 0 to 10 and is computed as follows:

DAS28-CRP = 0.56 * sqrt(TJC28) + 0.28 * sqrt(SJC28) + 0.36 * ln(CRP+1) + 0.014 * SGA + 0.96

The DAS28-CRP score corresponds to the current RA activity:

  • 0 to < 2.6 Remission
  • 2.6 to < 3.2 LDA
  • 3.2 to ≤ 5.1 Moderate activity
  • > 5.1 High activity
Week 48
DAS28-CRP Low Disease Activity (LDA) or Remission, Non-augmented
Tidsram: Week 48

The Disease Activity Score in 28 joints calculated with C-reactive protein (DAS28-CRP) score is a composite index providing a measure of disease activity, comprising:

  • TJC28, tender joint count of 28 joints (scale 0=best to 28=worst)
  • SJC28, swollen joint count of 28 joints (scale 0=best to 28=worst)
  • SGA, subject global assessment (0=best to 10=worst)
  • hsCRP (mg/L), high sensitivity C-reactive protein concentration (mg/L)

A total score ranges from 0 to 10 and is computed as follows:

DAS28-CRP = 0.56 * sqrt(TJC28) + 0.28 * sqrt(SJC28) + 0.36 * ln(CRP+1) + 0.014 * SGA + 0.96

The DAS28-CRP score corresponds to the current RA activity:

  • 0 to < 2.6 Remission
  • 2.6 to < 3.2 LDA
  • 3.2 to ≤ 5.1 Moderate activity
  • > 5.1 High activity
Week 48
Health Assessment Questionnaire Disability Index (HAQ-DI) MCID Response, All Completers
Tidsram: Week 48

HAQ-DI response based on the MCID of -0.22 from baseline.

The HAQ-DI is a questionnaire validated for RA self-assessment by subjects that contains 20 questions in the following 8 functional areas:

  • Dressing and grooming
  • Arising
  • Eating
  • Walking
  • Hygiene
  • Reach
  • Grip
  • Common daily activities

Scoring within each functional area is from 0 (without any difficulty) to 3 (unable to do). The total score is obtained by summing 8 area scores and dividing by 8. The total HAQ-DI score ranges from 0 to 3 and corresponds to the current degree of disability:

  • 0 to < 1 Mild difficulties to moderate disability
  • 1 to < 2 Moderate disability
  • 2 to 3 Severe to very severe disability
Week 48
Health Assessment Questionnaire Disability Index (HAQ-DI) Response (MCID -0.22), Non-augmented
Tidsram: Week 48

HAQ-DI response based on the MCID of -0.22 from baseline.

The HAQ-DI is a questionnaire validated for RA self-assessment by subjects that contains 20 questions in the following 8 functional areas:

  • Dressing and grooming
  • Arising
  • Eating
  • Walking
  • Hygiene
  • Reach
  • Grip
  • Common daily activities

Scoring within each functional area is from 0 (without any difficulty) to 3 (unable to do). The total score is obtained by summing 8 area scores and dividing by 8. The total HAQ-DI score ranges from 0 to 3 and corresponds to the current degree of disability:

  • 0 to < 1 Mild difficulties to moderate disability
  • 1 to < 2 Moderate disability
  • 2 to 3 Severe to very severe disability
Week 48
the American College of Rheumatology (ACR) 20 Response, Subjects With 1 Prior b/tsDMARD
Tidsram: Week 12

Response is defined as achieving at least 20% improvement from baseline to Week 12 in tender and swollen joint counts of 28 joints (scale 0=best to 28=worst) and 3 out of the following 5 measures: Health Assessment Questionnaire Disability Index (HAQ-DI) score (scale 0=no difficulty to 3=unable to do), subject global assessment (0=best to 10=worst), subject pain (0=no pain to 10=worst), evaluator's global assessment (0=best to 10=worst), or high sensitivity C-reactive protein (hsCRP) concentration (mg/L).

Week 12
the American College of Rheumatology (ACR) 20 Response, Subjects With 2 Prior b/tsDMARD
Tidsram: Week 12

Response is defined as achieving at least 20% improvement from baseline to Week 12 in tender and swollen joint counts of 28 joints (scale 0=best to 28=worst) and 3 out of the following 5 measures: Health Assessment Questionnaire Disability Index (HAQ-DI) score (scale 0=no difficulty to 3=unable to do), subject global assessment (0=best to 10=worst), subject pain (0=no pain to 10=worst), evaluator's global assessment (0=best to 10=worst), or high sensitivity C-reactive protein (hsCRP) concentration (mg/L).

Week 12
the American College of Rheumatology (ACR) 20 Response, Subjects With 3 Prior b/tsDMARD
Tidsram: Week 12

Response is defined as achieving at least 20% improvement from baseline to Week 12 in tender and swollen joint counts of 28 joints (scale 0=best to 28=worst) and 3 out of the following 5 measures: Health Assessment Questionnaire Disability Index (HAQ-DI) score (scale 0=no difficulty to 3=unable to do), subject global assessment (0=best to 10=worst), subject pain (0=no pain to 10=worst), evaluator's global assessment (0=best to 10=worst), or high sensitivity C-reactive protein (hsCRP) concentration (mg/L).

Week 12
the American College of Rheumatology (ACR) 20 Response, Subjects With >=4 Prior b/tsDMARD
Tidsram: Week 12

Response is defined as achieving at least 20% improvement from baseline to Week 12 in tender and swollen joint counts of 28 joints (scale 0=best to 28=worst) and 3 out of the following 5 measures: Health Assessment Questionnaire Disability Index (HAQ-DI) score (scale 0=no difficulty to 3=unable to do), subject global assessment (0=best to 10=worst), subject pain (0=no pain to 10=worst), evaluator's global assessment (0=best to 10=worst), or high sensitivity C-reactive protein (hsCRP) concentration (mg/L).

Week 12

Samarbetspartners och utredare

Det är här du hittar personer och organisationer som är involverade i denna studie.

Utredare

  • Huvudutredare: Mark Richardson, MD PhD, Massachusetts General Hospital
  • Huvudutredare: John Tesser, MD, Arizona Arthritis and Rheumatology Research, P.C.

Publikationer och användbara länkar

Den som ansvarar för att lägga in information om studien tillhandahåller frivilligt dessa publikationer. Dessa kan handla om allt som har med studien att göra.

Studieavstämningsdatum

Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.

Studera stora datum

Studiestart (Faktisk)

11 januari 2021

Primärt slutförande (Faktisk)

16 maj 2024

Avslutad studie (Beräknad)

1 oktober 2027

Studieregistreringsdatum

Först inskickad

31 augusti 2020

Först inskickad som uppfyllde QC-kriterierna

31 augusti 2020

Första postat (Faktisk)

7 september 2020

Uppdateringar av studier

Senaste uppdatering publicerad (Faktisk)

17 november 2026

Senaste inskickade uppdateringen som uppfyllde QC-kriterierna

13 november 2026

Senast verifierad

1 januari 2026

Mer information

Termer relaterade till denna studie

Plan för individuella deltagardata (IPD)

Planerar du att dela individuella deltagardata (IPD)?

NEJ

IPD-planbeskrivning

No sharing data is planned.

Läkemedels- och apparatinformation, studiedokument

Studerar en amerikansk FDA-reglerad läkemedelsprodukt

Nej

Studerar en amerikansk FDA-reglerad produktprodukt

Ja

Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .

Prenumerera